Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.


Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).

Apexigen’s Immuno-oncology Strategy

Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform  enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.


April 1, 2019
Apexigen Presents Clinical Data on CD40 Antibody APX005M in Metastatic Melanoma at the AACR Annual Meeting 2019

March 31, 2019
Apexigen Announces New Clinical Data on APX005M in Combination Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019

March 20, 2019
Apexigen Announces Clinical Data Presentations on CD40 Antibody APX005M at the AACR Annual Meeting 2019

February 19, 2019
Apexigen to present at upcoming Investor Conferences

Read more news.